Michael D. Lewis, MD Joins the BART Foundation’s Board

Dear Friends,

We’re thrilled to announce that Michael D. Lewis, MD, has joined the board of the BART Foundation. Dr. Lewis is a thought leader in the field of Omega-3 fish oil therapies for TBI/ABI, a distinguished physician, soldier, researcher, entrepreneur, public speaker, and advocate for many of the alternative therapies our foundation strives to promote and seek coverage for through health insurers. Dr. Lewis joins three other physicians on our board: Dr. Michael Compain, MD, Dr. Perry Perretz, DO, and Dr. Eugene Sussman, MD. We are incredibly thankful for his expertise and familiarity with athletes and Veterans who have sustained TBI/ABI.

Dr. Lewis is a graduate of the U.S. Military Academy at West Point and Tulane University School of Medicine and completed his postgraduate training at Walter Reed Army Medical Center, Johns Hopkins University, and Walter Reed Army Institute of Research. He is board-certified and a Fellow of the American College of Preventive Medicine and the American College of Nutrition. After a distinguished 31-year career in the U.S. Army, Dr. Lewis retired as a colonel and founded the nonprofit Brain Health Education and Research Institute and BrainCARE, which fosters better brain health for people worldwide. In addition, he is the author of When Brains Collide: What Every Athlete and Parent Should Know About the Prevention and Treatment of Concussions and Head Injuries, which details his research-based Omega-3 Protocol to assist the brain’s biochemical environment in improving the concussion healing process. To learn more, we encourage you to visit our Media page and watch our video interviews with Dr. Lewis, where he discusses diet, supplements, and current studies for physician-supervised Omega-3 use as a treatment for a range of brain injuries.

We look forward to working with Dr. Lewis in the months ahead as we continue to promote better outcomes for brain injury survivors by evaluating and promoting alternative therapies, watching global research and clinical trial outcomes, and sharing information in user-friendly language with the TBI/ABI community.